The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Schizophrenia and related disorders during mid- to late-life (R01, R21 Clinical Trial Optional)
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions.
This NOFO uses the R01 grant mechanism, while the companion NOFO (PAR-24-026), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.
- Letter of Intent: 30 days prior to the application due date
- R01 Due Dates: Feb. 5, June 5, Oct. 5
- R21 Due Dates: Feb. 16, June 16, Oct. 16
PAR-24-023 Expiration Date September 08, 2026
Areas of Interest
This NOFO is intended to support research designed to identify the neurobiological, behavioral, psychosocial, and environmental mechanisms underlying the onset, trajectory, and outcome of schizophrenia and related psychotic disorders in mid- to late-life, with consideration for the identification of novel targets for future development of prevention and intervention efforts. Studies that leverage concepts, methods, and findings emerging from geroscience research on mechanisms of normative and pathological aging as predictors of risk, trajectory, and outcome of schizophrenia and related psychotic disorders in mid- to late-life are encouraged.
Research must target populations in the mid- to late-life age range or mid-late life stages, but relevant comparison populations may include those who are younger if scientifically justified.